telavancin indications/contra

Stem definitionDrug idCAS RN
4116 372151-71-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • telavancin
  • arbelic
  • telavancin hydrochloride
  • vibativ
  • telavancin HCl
an anti-infective agent
  • Molecular weight: 1755.65
  • Formula: C80H106Cl2N11O27P
  • CLOGP: 1.87
  • LIPINSKI: 3
  • HAC: 38
  • HDO: 23
  • TPSA: 598.09
  • ALOGS: -5.08
  • ROTB: 30

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 11, 2009 FDA THERAVANCE BIOPHARMA

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 53.01 49.55 15 67 49668 3336109

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC J01XA03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Glycopeptide antibacterials
FDA EPC N0000191281 Lipoglycopeptide Antibacterial
FDA Chemical/Ingredient N0000191280 Lipoglycopeptides
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drug

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Bacterial pneumonia indication 53084003 DOID:874
Pneumonia due to Staphylococcus aureus indication 441658007
Complicated Skin and Skin Structure Streptococcus Agalactiae Infection indication
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection indication
Complicated Skin and Skin Structure Infection indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Torsades de pointes contraindication 31722008
Hypertensive disorder contraindication 38341003 DOID:10763
Chronic heart failure contraindication 48447003
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:2527
Prolonged QT interval contraindication 111975006
Decompensated cardiac failure contraindication 195111005
Impaired renal function disorder contraindication 197663003
Pregnancy, function contraindication 289908002
Pseudomembranous enterocolitis contraindication 397683000 DOID:0060185
Congenital long QT syndrome contraindication 442917000

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 250MG BASE/VIAL VIBATIV THERAVANCE BIOPHARMA N022110 Sept. 11, 2009 DISCN POWDER IV (INFUSION) 7351691 May 1, 2021 METHOD FOR TREATING BACTERIAL INFECTION
EQ 250MG BASE/VIAL VIBATIV THERAVANCE BIOPHARMA N022110 Sept. 11, 2009 DISCN POWDER IV (INFUSION) 7700550 May 1, 2021 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 750MG BASE/VIAL VIBATIV THERAVANCE BIOPHARMA N022110 Sept. 11, 2009 RX POWDER IV (INFUSION) 7351691 May 1, 2021 METHOD FOR TREATING BACTERIAL INFECTION
EQ 750MG BASE/VIAL VIBATIV THERAVANCE BIOPHARMA N022110 Sept. 11, 2009 RX POWDER IV (INFUSION) 7700550 May 1, 2021 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 250MG BASE/VIAL VIBATIV THERAVANCE BIOPHARMA N022110 Sept. 11, 2009 DISCN POWDER IV (INFUSION) 7008923 May 6, 2021 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
EQ 750MG BASE/VIAL VIBATIV THERAVANCE BIOPHARMA N022110 Sept. 11, 2009 RX POWDER IV (INFUSION) 7008923 May 6, 2021 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
EQ 250MG BASE/VIAL VIBATIV THERAVANCE BIOPHARMA N022110 Sept. 11, 2009 DISCN POWDER IV (INFUSION) 6635618 Sept. 11, 2023 METHOD FOR TREATING BACTERIAL INFECTION
EQ 750MG BASE/VIAL VIBATIV THERAVANCE BIOPHARMA N022110 Sept. 11, 2009 RX POWDER IV (INFUSION) 6635618 Sept. 11, 2023 METHOD FOR TREATING BACTERIAL INFECTION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

scroll-->
IDSource
4029465 VUID
N0000180310 NUI
C1453642 UMLSCUI
D06057 KEGG_DRUG
0701472ZG0 UNII
560130-42-9 SECONDARY_CAS_RN
473837 RXNORM
26725 MMSL
d07483 MMSL
4029465 VANDF
443552009 SNOMEDCT_US
443553004 SNOMEDCT_US
N0000180310 NDFRT
013290 NDDF
CHEMBL507870 ChEMBL_ID
C487637 MESH_SUPPLEMENTAL_RECORD_UI
DB06402 DRUGBANK_ID
CHEMBL3301680 ChEMBL_ID
3081362 PUBCHEM_CID
8504 INN_ID
CHEBI:71229 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Vibativ HUMAN PRESCRIPTION DRUG LABEL 1 52118-001 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 20 sections
Vibativ HUMAN PRESCRIPTION DRUG LABEL 1 52118-002 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 20 sections
Vibativ HUMAN PRESCRIPTION DRUG LABEL 1 62847-001 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 19 sections
Vibativ HUMAN PRESCRIPTION DRUG LABEL 1 62847-002 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 19 sections